Sign In
Buy NRXP
$4.05
-0.570 (-12.34%)
At Close: Jun 03, 2026
Aiming to be the first FDA-approved medication to treat suicidal depression Designed to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC) Comp
New Strong Buy Stocks for December 30th
07:21am, Monday, 30'th Dec 2024
CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.
New Strong Buy Stocks for December 26th
06:00am, Thursday, 26'th Dec 2024
EGAN,ACMR, AVO, BB and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 26, 2024.
New Strong Buy Stocks for December 24th
06:51am, Tuesday, 24'th Dec 2024
FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.
NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 27'th Nov 2024
NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jo
NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale)
NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript
07:51pm, Monday, 18'th Nov 2024
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman a
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer
04:05pm, Monday, 18'th Nov 2024
Industry veteran with extensive experience in key areas of focus Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities WILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update
04:05pm, Thursday, 14'th Nov 2024
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accele
WILMINGTON, Del. , Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it wi
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024
04:06pm, Thursday, 07'th Nov 2024
WILMINGTON, Del. , Nov. 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it w
The clinics are located in favorable locations, are revenue generating and EBITDA positive Clinics offer a comprehensive range of mental health services Acquisition is expected to be immediately accre
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
08:30am, Wednesday, 23'rd Oct 2024
MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc.
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
08:30am, Wednesday, 23'rd Oct 2024
MIAMI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and
